美国 · SEC FORM 4
AN2 Therapeutics, Inc.
ANTX · Nasdaq · CIK 0001880438 · Healthcare · Biotechnology
内部人信号
1 qualifying P purchase group
当前 180 天评分窗口
20 同一窗口内观察到的 Form 4 交易行
11 sales · 8 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
Showing the six most active owners; 3 additional owner(s) remain in Form 4 申报证据.
买方广度与集中度
Roles in the peak window: Director. Concentration uses priced qualifying P lines only and does not change the saved score.
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2026-09-01 · FitzPatrick Margaret M.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
市场背景补充近期价格表现与风险信息，不影响内部人信号。
价格表现
- 1M
- -4.0%
- 3M
- +29.5%
- 6M
- +74.6%
- 12M
- —
波动率与流动性
- 波动率
- 132.0%
- Beta
- —
- 平均每日成交额
- —
估值
- 市值
- —
- P/E
- —
基本面
- 利润率
- —
- ROE
- -66.3%
- 细分行业
- Biotechnology
市场数据
价格数据截至：2026-10-03 · 价格来源：OpenBB/yfinance · 来自 SEC 申报文件：ROE · 财年截止日：2025-12-31 · Status: PASS
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 2,491,971
- 上期报告
- 2,397,307
- 日均成交量
- 261,160
- 回补天数
- 9.5
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-01 | FitzPatrick Margaret M | 买入 (P) | Common Stock | 2,098 | USD 5.53 | USD 11,602 | SEC 申报 ↗ |
| 2025-06-02 | Easom Eric | 买入 (P) | Common Stock | 10,000 | USD 1.07 | USD 10,700 | SEC 申报 ↗ |
| 2025-05-28 | FitzPatrick Margaret M | 买入 (P) | Common Stock | 8,610 | USD 1.18 | USD 10,160 | SEC 申报 ↗ |
| 2024-12-10 | Readnour Robin Shane | 买入 (P) | Common Stock | 5,000 | USD 1.49 | USD 7,450 | SEC 申报 ↗ |
| 2024-12-09 | Readnour Robin Shane | 买入 (P) | Common Stock | 30,772 | USD 1.43 | USD 44,004 | SEC 申报 ↗ |
| 2024-12-06 | Readnour Robin Shane | 买入 (P) | Common Stock | 19,228 | USD 1.45 | USD 27,881 | SEC 申报 ↗ |
| 2024-11-27 | Zakrzewski Joseph S | 买入 (P) | Common Stock | 2,000 | USD 1.40 | USD 2,800 | SEC 申报 ↗ |
| 2024-11-27 | Readnour Robin Shane | 买入 (P) | Common Stock | 25,000 | USD 1.42 | USD 35,500 | SEC 申报 ↗ |
| 2024-11-26 | Readnour Robin Shane | 买入 (P) | Common Stock | 12,500 | USD 1.39 | USD 17,375 | SEC 申报 ↗ |
| 2024-11-20 | Readnour Robin Shane | 买入 (P) | Common Stock | 50,000 | USD 1.15 | USD 57,750 | SEC 申报 ↗ |
| 2024-11-19 | Readnour Robin Shane | 买入 (P) | Common Stock | 150,000 | USD 1.03 | USD 155,250 | SEC 申报 ↗ |
| 2024-11-19 | Zakrzewski Joseph S | 买入 (P) | Common Stock | 5,000 | USD 1.01 | USD 5,050 | SEC 申报 ↗ |
| 2024-11-18 | Zakrzewski Joseph S | 买入 (P) | Common Stock | 20,000 | USD 1.00 | USD 20,000 | SEC 申报 ↗ |
| 2024-11-18 | Easom Eric | 买入 (P) | Common Stock | 50,000 | USD 1.00 | USD 50,000 | SEC 申报 ↗ |
| 2024-08-14 | Leonard Braden Michael | 买入 (P) | Common Stock | 1,500,000 | USD 1.04 | USD 1,560,000 | SEC 申报 ↗ |
Form 4 申报证据
42 transaction lines in the latest 365-day window; 217 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-12 | Martin Patricia A. | 奖励／授予 (A) | Common Stock | 389 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-10-12 | Marks Gilbert Lynn | 奖励／授予 (A) | Common Stock | 2,283 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-10-12 | Aziz Kabeer | 奖励／授予 (A) | Common Stock | 2,465 | USD 0.00 | USD 0 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-12 | Martin Patricia A. | 奖励／授予 (A) | Common Stock | 389 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-10-12 | Marks Gilbert Lynn | 奖励／授予 (A) | Common Stock | 2,283 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-10-12 | Aziz Kabeer | 奖励／授予 (A) | Common Stock | 2,465 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-09-15 | Trenor Cameron C. III | 奖励／授予 (A) | Common Stock | 116,667 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-09-09 | Readnour Robin Shane | 卖出 (S) | Common Stock | 1,108 | USD 6.02 | USD 6,670 | SEC 申报 ↗ |
| 2026-09-08 | Readnour Robin Shane | 卖出 (S) | Common Stock | 10,019 | USD 6.02 | USD 60,314 | SEC 申报 ↗ |
| 2026-09-03 | Readnour Robin Shane | 卖出 (S) | Common Stock | 6,100 | USD 6.07 | USD 37,027 | SEC 申报 ↗ |
| 2026-09-01 | Williams Sarah Joanne | 卖出 (S) | Common Stock | 272 | USD 5.53 | USD 1,504 | SEC 申报 ↗ |
| 2026-09-01 | FitzPatrick Margaret M | 买入 (P) | Common Stock | 2,098 | USD 5.53 | USD 11,602 | SEC 申报 ↗ |
| 2026-08-17 | Readnour Robin Shane | 卖出 (S) | Common Stock | 35,402 | USD 6.01 | USD 212,766 | SEC 申报 ↗ |
| 2026-08-14 | Zakrzewski Joseph S | 赠与 (G) | Common Stock | 405,880 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-07-10 | Martin Patricia A. | 奖励／授予 (A) | Common Stock | 766 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-07-10 | Marks Gilbert Lynn | 奖励／授予 (A) | Common Stock | 2,789 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-07-10 | Aziz Kabeer | 奖励／授予 (A) | Common Stock | 2,852 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-07-08 | Eizen Joshua M | 卖出 (S) | Common Stock | 5,945 | USD 4.17 | USD 24,791 | SEC 申报 ↗ |
| 2026-05-29 | Williams Sarah Joanne | 卖出 (S) | Common Stock | 265 | USD 4.43 | USD 1,174 | SEC 申报 ↗ |
| 2026-04-10 | Martin Patricia A. | 奖励／授予 (A) | Common Stock | 1,192 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-04-10 | Marks Gilbert Lynn | 奖励／授予 (A) | Common Stock | 3,775 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-04-10 | Aziz Kabeer | 奖励／授予 (A) | Common Stock | 3,775 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-03 | Williams Sarah Joanne | 卖出 (S) | Common Stock | 327 | USD 1.06 | USD 347 | SEC 申报 ↗ |
| 2026-02-20 | Williams Sarah Joanne | 奖励／授予 (A) | Common Stock | 48,375 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-20 | Eizen Joshua M | 奖励／授予 (A) | Common Stock | 50,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-20 | Easom Eric | 奖励／授予 (A) | Common Stock | 112,250 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-20 | Day Lucy | 奖励／授予 (A) | Common Stock | 38,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-20 | Chanda Sanjay | 奖励／授予 (A) | Common Stock | 38,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-12 | Martin Patricia A. | 奖励／授予 (A) | Common Stock | 3,650 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-12 | Marks Gilbert Lynn | 奖励／授予 (A) | Common Stock | 11,560 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-12 | Aziz Kabeer | 奖励／授予 (A) | Common Stock | 11,560 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-06 | Prior Stephen David | 卖出 (S) | Common Stock | 2,858 | USD 1.01 | USD 2,887 | SEC 申报 ↗ |
| 2026-01-06 | Eizen Joshua M | 卖出 (S) | Common Stock | 6,931 | USD 1.01 | USD 7,000 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | ANTX |
| CIK | 0001880438 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 217 transaction lines from 2022-03-29 to 2026-10-12 35 P purchase lines · 103 S sale lines · 79 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.